Steris (STE) fundamentals: P/E, valuation, undervalued?
Steris · Health Care · ref. ETF XLV · price $217.77
In short — Steris trades at 26.8× earnings (P/E), 17.8× forward, with a net margin of 13.3 % and revenue growth of +7 %. Read: Fairly valued (P/E 18 in line with ~14% growth (PEG 1.3)).
Is Steris stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$217.77-8.4% over range
Oct 14, 25low $199.4 · high $268.65Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
100% recommend buying · 3 analysts
Valuation : Fairly valued — P/E 18 in line with ~14% growth (PEG 1.3)
Valuation
26.8
P/E (price/earnings)
17.8
Forward P/E
1.91
PEG
2.9
Price/book (P/B)
$21.2B
Market cap
8.13
EPS
Profitability & growth
13.3 %
Net margin
+7 %
Revenue growth
+14 %
Earnings growth
$2.0B
Total debt
Steris income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2023 | $5.0B | $107M | 2.2 % |
| 2024 | $5.5B | $378M | 6.9 % |
| 2025 | $5.5B | $615M | 11.3 % |
| 2026 | $5.9B | $782M | 13.2 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Steris's P/E and is the stock undervalued? What's a good P/E?
Steris's P/E is 26.8 (forward 17.8). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Fairly valued".
Is Steris profitable?
Steris has a net margin of 13.3 % (EPS 8.13). The company is profitable.
Is STE stock expensive?
Our read: "Fairly valued" — P/E 18 in line with ~14% growth (PEG 1.3). Cross-check with growth and sector.
💬 A question about Steris? The JPI assistant answers using our backtest data.